Cohance Pashamylaram Plant Gets USFDA VAI Classification
On 7 November 2026, Cohance Lifesciences said the USFDA classified its Pashamylaram, Hyderabad plant as VAI, formally closing the July-August inspection.
On 7 November 2026, Cohance Lifesciences said the USFDA classified its Pashamylaram, Hyderabad plant as VAI, formally closing the July-August inspection.
Gland Pharma Q2 FY27 net profit rises 58% to ₹291 crore as revenue grows 23% to ₹1,834 crore, led by 31% CDMO growth and a 42% jump in US sales.
Symbiotec signs a 10-year take-or-pay CDMO agreement with a European innovator for fermentation-based alternative protein at its Ujjain campus.
Neuland Labs’ Q2 FY27 profit fell 47% to ₹51.1 crore as income slipped 11%, while the API maker opened a new peptide plant and bought land in Kakinada.
Granules India’s Q2 FY27 net profit rose 39% to ₹182 crore on 20% revenue growth, with three first-to-file ANDAs and five US launches lined up.
Akums Q2 FY27 profit rose 168% to ₹115 crore as revenue grew 31.9% to ₹1,342 crore and its CDMO business, now 83% of sales, grew 38.6%.
OneSource Specialty Pharma has received a USFDA EIR with VAI classification for its Bengaluru Sterile Product Division, closing the June 2026 inspection.
Alivus Life Sciences (formerly Glenmark Life Sciences) posted Q2 FY27 revenue of Rs 682 crore, up 16%, and PAT of Rs 197 crore, up 51.3%. Non-Glenmark sales rose 20.8% to 79% of revenue, CDMO revenue grew about 80% to Rs 50 crore, and Solapur Phase 1 goes live in Q3 FY27.
Laurus Labs reported Q2 FY27 net profit of ₹441 crore, up 126%, on revenue of ₹2,206 crore, as CDMO revenue rose 75% to ₹904 crore and EBITDA margin widened to 34.5%. The Hyderabad drugmaker also agreed to take a 60% stake in Montreal-based Galenvs Sciences to deepen its oligonucleotide capabilities.
Swiss B2B pharma company Adalvo has acquired Pune-based Enzene’s romiplostim biosimilar programme referencing Amgen’s Nplate, while Enzene stays on as development and manufacturing partner and sharpens its focus on biologics CDMO services.
Nucelion Therapeutics, the cell and gene therapy CDMO arm of Bharat Biotech, will provide process development and GMP manufacturing support for two Pandorum Technologies ophthalmology programmes in advanced keratopathy and wet AMD, with a combined outlay of ₹16.97 crore including up to ₹8 crore under the Centre’s PRIP scheme.
Syngene International’s Q2 FY27 revenue rose 13% quarter-on-quarter to ₹833 crore and operating EBITDA margin improved six points to 18%, helped by CDMO traction, while the company signed its first manufacturing agreement for its Bayview biologics facility in the US.
Morepen Laboratories reported Q2 FY27 revenue of ₹755 crore, up 81%, and EBITDA of ₹132 crore, up 273%, as its CDMO business hit commercial scale, exports more than doubled and it filed its first US ANDA.